Finally, PIK3CA mutations, such as E542K, E545K, and H1047R, underscore the relevance of the PI3K/AKT/mTOR pathway in NSCLC and hold promise for future targeted therapies [40,41]. This evidence concerns the gene MTOR and non-small cell lung carcinoma.